Xianfen Zhang

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIMS To assess the incidence and risk of arterial and venous thromboembolic events (ATEs and VTEs) associated with antivascular endothelial growth factor (VEGF) agents, including VEGF receptor-tyrosine kinase inhibitors and VEGF monoclonal antibodies, in advanced non-small-cell lung cancer (NSCLC) patients. METHODS We performed a broad search of PubMed(More)
  • 1